Business + Public Policy Business with Benevolence September 15, 2016 At Censeo Consulting Group, founded by Carnegie Mellon alumnus Raj Sharma, improving the bottom line doesn’t come at the expense of others.
Arts & Culture + Public Policy Remembering 9/11 September 9, 2016 | By Melissa Silmore Carnegie Mellon Alumna Regina Ress shares her stories of “Compassion, Generosity and Grace.”
Science + Public Policy Eat Healthier, Plan Ahead September 7, 2016 | By Shannon Deep Want to make better food choices when buying a meal? Order well ahead of time, says CMU alumnus Eric VanEpps.
Public Policy + Innovation Startup Fledglings August 3, 2016 | By Mark Kramer Fledge, founded by Carnegie Mellon alumnus Michael Libes, calls itself the “conscious company” accelerator, and for good reason.
Public Policy + Innovation Feeding the Hungry July 26, 2016 | By Elizabeth Shestak Carnegie Mellon alumna Leah Lizarondo has cooked up a “fresh” approach.
Technology + Public Policy Do Not Disturb June 13, 2016 | By Sasha Kerbel Carnegie Mellon University is a leader in data-privacy research and education. Faculty members lead some of the largest research projects in the country and also serve as frequent contributors to public-policy activities in this fast-moving space. So it’s no surprise that CMU embraced locally the global event, Data Privacy Day.
Public Policy + Technology Presidential Innovation Fellows Tackle Nation’s Most Pressing Challenges April 25, 2016 | By Jennie Dorris Improve cybersecurity? Writing the robotics roadmap? Reduce the backlog of veterans’ claims? Members of the Carnegie Mellon University community are among a select group of fellows solving these problems.
Arts & Culture + Public Policy Marijuana: Past, Present, Future February 22, 2016 | By Jennie Dorris Although cannabis is still classified by the federal government as a Schedule I drug (the category for all banned substances that have no recognized medical value), more and more states are legalizing large-scale commercial production for medical and, in some cases, non-medical use. The ramifications, according to drug-policy experts from Carnegie Mellon University, are wide-ranging—from criminal, economic, and health perspectives.